Mergers And Acquisitions In Indian Pharmaceutical Industry Pdf
File Name: mergers and acquisitions in indian pharmaceutical industry .zip
- Mergers and Acquisitions in the Indian Pharmaceutical Industry: Nature, Structure and Performance
- Performance of Mergers and Acquisitions in the Pharmaceutical Industry: A Comparative Perspective
- Mergers & acquisitions pharma industry
- Sun Pharma
An increasing number of pathogenic bacteria have. It is primarily, a problem with pharmaceuticals that are still in patent, since the price of the. Budgets are up The 30 research pharmaceutical, existed in had by successively merged to become only 9, companies.
Mergers and Acquisitions in the Indian Pharmaceutical Industry: Nature, Structure and Performance
Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. Narayanan and A. Narayanan , A. Ramanathan Published Business. The phenomenon is considered to be the most important strategy for gaining competitive advantage for firms. Save to Library.
Performance of Mergers and Acquisitions in the Pharmaceutical Industry: A Comparative Perspective
Actively scan device characteristics for identification. Use precise geolocation data. Select personalised content. Create a personalised content profile. Measure ad performance. Select basic ads. Create a personalised ads profile.
Show all documents A survey methodology was used to examine group differences, comparing those from the two pre-merger companies and those newly merged organization. Results revealed that group differences in both sources and effects of stress existed. Those from the dominant pre- merger company reported the highest stress levels and most negative work attitudes. Thus this deal was beneficial for both Jet Airways and Air Sahara.
Andrade, G. Basant, R. Beena, P. Black, B. Blonigen, B.
Mergers & acquisitions pharma industry
The system can't perform the operation now. Try again later. Citations per year.
Show all documents In other words, firms do not necessarily benefit from MA in terms of profitability in the long-run, which is largely in the line of observations made by Ikeda and Doi , Cosh et al , Kumar , Geroski and Odagiri that either confirm negative results or find little changes in operating performance following MA. However, the observation of no statistically significant influence of MA on profitability contradicts with the findings of Healy et al. The contradiction may largely be due to multi-directional structure-conduct- performance -policy relationships used in the present paper.
This paper tries to address the extent, nature and impact of the recent surge in consolidation strategies especially in the form of mergers and acquisitions followed by the firms in the Indian pharmaceutical industry. The study found that many of the firms are implementing these strategies in the new context of globalisation mainly to overcome the acute competition arising out of the pro-market reforms and to strengthen their market portfolio.
Demirbag, M. Emerald Group Publishing Limited. Report bugs here. Please share your general feedback. You can join in the discussion by joining the community or logging in here. You can also find out more about Emerald Engage.
In the context of acquisition, there is a riskiness associated with the any business strategy, for to which a firm may choose to finance the deal either via cash, stock or assets. The factors such as capital intensity were found more important when acquisition by share was undertaken compared to others. Any gap in the flow of drugs to the market would hamper the growth of the firm.
The TRIPs Agreement has led to a reinforcement of the protection of intellectual property, particularly in many developing countries. From the point of view of transfer of technology, the imitation of technologies from industrialized countries and the marketing of the resulting products will now be more difficult. The MNCs are also expanding vigorously in the generic segments.
Show all documents Mergers and Acquisitions in the Indian Pharmaceutical Industry: Nature, Structure and Performance Firms may opt for mergers in order to reduce the risk and uncertainty. If a firm is more diversified, then there is greater possibility of obtaining stable return. Any losses in one particular market can be offset by profit in some other market.
The company offers formulations in various therapeutic areas, such as cardiology , psychiatry , neurology , gastroenterology and diabetology. It also provides APIs such as warfarin , carbamazepine , etodolac , and clorazepate , as well as anti-cancers , steroids , peptides , sex hormones , and controlled substances.